Literature DB >> 1865992

Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice.

U Bickel1, T Thomsen, J P Fischer, W Weber, H Kewitz.   

Abstract

Galanthamine was determined in plasma and tissue extracts of mice, after the application of 4, 6 and 8 mg/kg (i.v.), by reverse phase HPLC, with fluorescence detection. A biexponential decline of concentrations in plasma, with a terminal half-life of 43.3 min, was observed after the dose of 4 mg/kg. The volume of distribution (Vss) of 2.17 l/kg was similar to that found in other species, including man. Metabolism to the inactive diastereomer, epigalanthamine, was very limited. There was a rapid accumulation of galanthamine in tissues, which was most pronounced in the kidney (10-fold compared to plasma) and liver (5-fold). In brain, accumulation was similar to other parenchymatous organs (diaphragm, lung) and amounted to 2.10-fold. Red blood cells showed a concentration 1.34-fold greater than plasma. The accumulation of galanthamine in tissue, with the exception of liver and kidney, can be explained by passive distribution according to differences in pH, between intra- and extracellular compartments. Extraction of galanthamine from blood to brain tissue was complete, indicated by a clearance in the range of cerebral blood flow (1.05 ml min-1 g-1). The concentration-time course of galanthamine in brain tissue was parallel to that in plasma during the terminal elimination phase. Measurement of inhibition of acetylcholinesterase (AChE) in the same samples from brain revealed a maximum apparent inhibition of 43% in the homogenate of brain (1:4 w/v in phosphate buffer, 4 mg/kg, 5 min after injection).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1865992     DOI: 10.1016/0028-3908(91)90005-v

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  14 in total

Review 1.  How to measure drug transport across the blood-brain barrier.

Authors:  Ulrich Bickel
Journal:  NeuroRx       Date:  2005-01

2.  Chronic treatment with galantamine rescues reversal learning in an attentional set-shifting test after experimental brain trauma.

Authors:  Ihuoma Njoku; Hannah L Radabaugh; Melissa A Nicholas; Lindsay A Kutash; Darik A O'Neil; Ian P Marshall; Jeffrey P Cheng; Anthony E Kline; Corina O Bondi
Journal:  Exp Neurol       Date:  2019-01-31       Impact factor: 5.330

Review 3.  Galantamine: a review of its use in Alzheimer's disease.

Authors:  L J Scott; K L Goa
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

4.  Galantamine and Environmental Enrichment Enhance Cognitive Recovery after Experimental Traumatic Brain Injury But Do Not Confer Additional Benefits When Combined.

Authors:  Patricia B de la Tremblaye; Corina O Bondi; Naima Lajud; Jeffrey P Cheng; Hannah L Radabaugh; Anthony E Kline
Journal:  J Neurotrauma       Date:  2016-12-20       Impact factor: 5.269

5.  The acetylcholinesterase inhibitors competitively inhibited an acetyl L-carnitine transport through the blood-brain barrier.

Authors:  Na-Young Lee; Hyung-Ok Choi; Young-Sook Kang
Journal:  Neurochem Res       Date:  2012-02-23       Impact factor: 3.996

Review 6.  Galanthamine.

Authors:  B Fulton; P Benfield
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

7.  Galanthamine in Alzheimer's disease : a new alternative to tacrine?

Authors:  M Rainer
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

8.  Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway.

Authors:  Valentin A Pavlov; William R Parrish; Mauricio Rosas-Ballina; Mahendar Ochani; Margot Puerta; Kanta Ochani; Sangeeta Chavan; Yousef Al-Abed; Kevin J Tracey
Journal:  Brain Behav Immun       Date:  2008-06-27       Impact factor: 7.217

Review 9.  Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.

Authors:  C Sadowsky; J A Davila Perez; R W Bouchard; I Goodman; S Tekin
Journal:  CNS Neurosci Ther       Date:  2010       Impact factor: 5.243

10.  Central cholinergic activation of a vagus nerve-to-spleen circuit alleviates experimental colitis.

Authors:  H Ji; M F Rabbi; B Labis; V A Pavlov; K J Tracey; J E Ghia
Journal:  Mucosal Immunol       Date:  2013-07-24       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.